Bascom Palmer Angiogenesis - 2013 Brochure pdf

More documents

Recommendations

Info

BASCOM PALMER EYE INSTITUTEAngiogenesis,Exudation,and Degeneration2013Bascom Palmer Eye Instituteinvites you to join us in February2013 for our tenth annualangiogenesis meeting. Thisunique and exciting symposiumentitled Angiogenesis,Exudation, and Degeneration 2013 will be held February9, 2013 at the Mandarin Oriental Hotel in Miami, Florida.The meeting will feature an exceptional gathering ofbasic scientists, clinicians, and healthcare experts, allfocused on understanding and treating neovascular andexudative diseases of the eye. The meeting will highlightthe revolutionary pharmacotherapies now in developmentand clinical practice for the management of neovascularAMD, macular edema, diabetic retinopathy, and retinopathyof prematurity with a special emphasis on the presentand future financial impact of these drugs on clinicalpractices and Medicare.Mandarin Oriental, Miami
COURSE CO-DIRECTORSPhilip J. Rosenfeld, MD, PhDProfessor of OphthalmologyBascom Palmer Eye InstituteUniversity of Miami Miller School of MedicineCourse Co-Director, Angiogenesis 2013Harry W. Flynn, Jr., MDProfessor of OphthalmologyThe J. Donald M. Gass DistinguishedChair in OphthalmologyBascom Palmer Eye InstituteUniversity of Miami Miller School of MedicineCourse Co-Director, Angiogenesis 2013Carmen A. Puliafito, MD, MBADean, Keck School of MedicineMay S. and John Hooval Dean’s Chair in MedicineProfessor of Ophthalmology and Health ManagementDoheny Eye InstituteUniversity of Southern CaliforniaCourse Co-Director, Angiogenesis 2013COURSE DESCRIPTIONAngiogenesis 2013 follows the tradition of excellenceestablished by the widely acclaimed Angiogenesisprograms between 2004 and 2012. Designed for retinalspecialists, general ophthalmologists and researchers, thecurrent program will review the latest therapies forexudative eye diseases and the use of these newtreatments in clinical practice. We will emphasize currentand future treatments for a broad spectrum of retinaldiseases with special emphasis on age-related maculardegeneration and diabetic retinopathy.COURSE OBJECTIVESUpon completion of this program, participants shouldbe able to:• Enhance patient care by evaluating the current global useof anti-VEGF drugs for exudative ocular diseases• Manage patients with anti-VEGF therapy through thepreferred dosing practices• Improve management skills by evaluating all the risksassociated with injections of anti-VEGF drugs• Analyze results of clinical trials in exudative maculardiseases and apply to clinical practice• Evaluate the benefits and limitations of combinationtherapies for exudative diseases• Evaluate the benefits and limitations of different imagingstrategies for age-related macular degeneration• Enhance patient care by analyzing the genetic basis fordifferent macular and retinal degenerative conditions• Analyze the rationale for emerging treatments for differentmacular and retinal degenerative conditions
Page 1: Angiogenesis,Exudation, andDegenera
Page 5 and 6: 10:10 Visual Cycle Modulation in Dr
Page 7 and 8: 4:40 Anti-Sphingosine-1-Phosphate M
Page 9 and 10: Glenn J. Jaffe, MDProfessor of Opht
Page 11 and 12: MEETINGREGISTRATIONFORMBascom Palme

Bascom Palmer Angiogenesis - 2013 Brochure pdf

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?